<DOC>
	<DOCNO>NCT00943761</DOCNO>
	<brief_summary>This study provide vaniprevir 600 mg 300 mg twice daily combination pegylated interferon ( peg-IFN ) ribavirin ( RBV ) participants chronic hepatitis C virus ( HCV ) infection achieve viral eradication participate prior vaniprevir clinical trial ( MK-7009-004 , NCT00518622 ; MK-7009-007 , NCT00704405 ; MK-7009-009 , NCT00704184 ; MK-7009-029 , NCT00954993 ) .</brief_summary>
	<brief_title>A Study Vaniprevir ( MK-7009 ) Participants With Chronic Hepatitis C Infection After Participation Other Vaniprevir Studies ( MK-7009-028 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Inclusion criterion : Participant participate prior vaniprevir clinical trial Participant agree use acceptable birth control method treatment Exclusion criterion : More one year pass since participant determine eligible enrollment protocol 028 Participant discontinue vaniprevir and/or pegIFN and/or RBV prior study due safety tolerability issue Participant receive investigational therapy HCV participate prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hepatitis C</keyword>
</DOC>